Predictive Oncology Plunges 10.06% Amid AI Drug Discovery Push

On March 26, 2025, Predictive Oncology's stock experienced a significant drop of 10.06% in pre-market trading, reflecting investor sentiment and market dynamics.

Predictive Oncology has made substantial strides in its AI-driven drug discovery efforts. The company successfully developed predictive models derived from 21 unique compounds, focusing on prevalent cancer indications such as breast, colon, and ovary. These models represent a significant advancement in drug discovery, leveraging the company's active machine learning platform.

In a strategic move, Predictive Oncology completed the sale of its Skyline Medical assets to DeRoyal Industries. This transaction allows the company to focus more intently on its core AI-driven drug discovery capabilities and integrate seamlessly with Renovaro Biosciences. The deal positions the STREAMWAY® Systems with an established market leader, driving accelerating growth.

Predictive Oncology is also moving forward with a definitive merger agreement with Renovaro Biosciences. This merger will facilitate the integration of AI/ML platform technologies, core laboratory capabilities, and business development efforts across Europe and the United States. Renovaro’s recent acquisition of BioSymetrics further expands Predictive Oncology’s biomarker capabilities, enhancing its competitive edge in the market.

Additionally, Predictive Oncology has reported positive results from its AI-driven drug repurposing efforts. The company successfully identified several abandoned or discontinued drugs for further testing and development in ovarian and other cancer types. This creates significant business development opportunities with large pharmaceutical companies, offering meaningful long-term commercial potential.